Please use this identifier to cite or link to this item:
Title: Survival of adults with primary malignant brain tumours in Europe ; results of the EUROCARE-5 study
Authors: Visser, Otto
Ardanaz, Eva
Botta, Laura
Sant, Milena
Tavilla, Andrea
Minicozzi, Pamela
Calleja, Neville
Keywords: Brain -- Tumors
Health surveys
Tumors -- Patients -- Long-term care
Issue Date: 2015
Publisher: Elsevier Ltd.
Citation: Visser, O., Ardanaz, E., Botta, L., Sant, M., Tavilla, A., Minicozzi, P. & Calleja, N. (2015). Survival of adults with primary malignant brain tumours in Europe ; results of the EUROCARE-5 study. European Journal of Cancer, 51(15), 2231-2241.
Abstract: Background: Primary malignant brain tumours are rare but represent a serious health burden due to their poor survival. This manuscript describes the survival of malignant brain tumours in adults diagnosed 2000–2007 in Europe. Methods: For this study we analysed patients archived in 86 European population-based cancer registries, followed up to 31st December 2008. Only primary malignant neuroepithelial brain tumours (with pathological confirmation) and primary malignant unspecified brain tumours without pathological confirmation were included. We estimated 1-year and 5-year relative survival (RS) weighted by age group and country. We also estimated country-specific and age-specific survival, together with survival differences between time periods (for 1999–2001, 2002–2004 and 2005–2007). Results: Glioblastoma represents 49% of all brain tumours, followed by other/unspecified astrocytoma (18%), oligodendroglioma/oligoastrocytoma (9%), ependymoma (1.5%) and embryonal tumours (1%). Five-year RS was 20% for all tumours combined, but ranged from 58% for ependymoma to only 6% for glioblastoma and sharply decreased with increasing age. Differences between countries were relatively small, but generally RS in Ireland/United Kingdom (UK) and Eastern Europe was below the average. An increase in 1-year RS (up to 10–12%) was noted over time, being largest in Central and Northern Europe in patients between 45 and 74 years of age. Conclusions: Despite an increase in 1-year RS in most European regions, the survival of primary malignant brain tumours is still poor. Disparities between countries were evident, being even larger at the end of the study period than at the beginning, suggesting differences in availability of the latest treatment modalities.
Appears in Collections:Scholarly Works - FacM&SPH

Files in This Item:
File Description SizeFormat 
  Restricted Access
2.08 MBAdobe PDFView/Open Request a copy

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.